Table1.

Comparison of baseline clinical characteristic between groups

Characteristics	Responders (n = 70)	Non-responders (n = 16)	P value	Non-recurrent eyes (n = 44)	Recurrent eyes (n = 26)	P value
Mean ± SD (range)
Age (years)	66.7 ± 6.5 (52–83)	65.4 ± 3.7 (54–70)	0.280a	66.0 ± 6.9 (52–80)	67.9 ± 6.0 (60–83)	0.263a
Baseline BCVA (LogMAR)	0.39 ± 0.33 (0.00–1.70)	0.51 ± 0.29 (0.10–1.10)	0.191a	0.43 ± 0.37 (0.00–1.70)	0.34 ± 0.26 (0.00–0.90)	0.291a
Refractive error (diopter)	0.13 ± 1.36 (−3.50–3.00)	0.31 ± 0.73 (−1.00–1.25)	0.601a	−0.02 ± 1.43 (−3.50–3.00)	0.38 ± 1.24 (−2.75–3.00)	0.243a
Previous anti-VEGF treatments (n)	2.9 ± 3.2 (0–11)	2.6 ± 3.4 (0–10)	0.796a	2.7 ± 3.1 (0–11)	3.2 ± 3.4 (0–11)	0.554a
Central macular thickness (μm),	369 ± 109 (141–843)	378 ± 70 (232–455)	0.781a	379 ± 129 (141–843)	354 ± 66 (254–540)	0.362a
GLD of lesion (μm)	2458 ± 737 (1034–4735)	2543 ± 791 (1276–4182)	0.718a	2403 ± 821 (1034–4735)	2544 ± 591 (1515–4233)	0.450b
Number of polyps (n)	2.0 ± 1.6 (1–9)	1.7 ± 1.0 (1–4)	0.555a	2.0 ± 1.6 (1–9)	2.0 ± 1.7 (1–9)	0.927a
Height of PED (μm)	247 ± 172 (0–805)	224 ± 111 (0–471)	0.623a	272 ± 173 (0–805)	209 ± 167 (0–601)	0.337a
n (%)
Gender (male/female)	49/21	12/4	0.750c	28/16	21/4	0.073c
Treatment-naive eyes	35 (50)	11 (68)	0.175c	21 (48)	14 (54)	0.976c
Choroidal hyperpermeability	31 (44)	2 (13)	0.018c	19 (43)	12 (46)	0.809c
Presence of fluid
Subretinal	69 (99)	15 (94)	0.248c	44 (100)	25 (96)	0.190c
Intraretinal	12 (17)	0 (0)	0.086c	8 (18)	4 (27)	0.668c
PED	60 (86)	13 (81)	0.706c	38 (86)	22 (85)	0.293c
Lesion location			0.782c			0.498c
Macula	68 (97)	16 (100)		43 (98)	25 (96)
Peripapillary	2 (10)	0 (0)		1 (2)	1 (4)

SD standard deviation, BCVA best-corrected visual acuity, VEGF vascular endothelial growth factor, GLD greatest linear dimension identified by indocyanine angiography, PED pigment epithelial detachment.

^aMann–Whitney test between groups

^bStudent’s t-test between groups

^cChi-square test between groups